Sanofi S.A., FR0000120578

Sanofi stock: At Lang & Schwarz, Sanofi stock gains 3.54 percent

Published on 10/21/2026 at 15:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 30, 2026. Sanofi stock costs EUR 73.52 on October 21, 2026, up 3.54 percent versus the Xetra close.

Sanofi moves above Xetra close

Sanofi stock stood 3.54 percent above its October 20, 2026 Xetra close on October 21, 2026.
RBC Capital maintained a Hold rating and a EUR 75.00 target in a report released October 20, 2026.
Sanofi stock costs EUR 73.52 at Lang & Schwarz on October 21, 2026 at 3:02 p.m. CEST, 3.54 percent above the Xetra close of October 20, 2026.
Sanofi will publish third-quarter 2026 results on October 30, 2026.

Bold pop-art comic illustration of a gloved hand holding a glowing cyan syringe with radial energy lines on a violet halftone dot background — Sanofi FR0000120578 bold pop-art comic illustration of gloved hand holding glowing syringe with violet-cyan energy, Illustration mit AI erstellt.

Sanofi stock stood 3.54 percent above the Xetra close of October 20, 2026 during October 21, 2026 trading. The move puts the pharmaceutical company at EUR 73.52 at Lang & Schwarz, while the next quarterly report is scheduled for October 30, 2026.

At 3:02 p.m. CEST on October 21, 2026, Sanofi traded at EUR 73.52 at Lang & Schwarz, up 3.54 percent against the EUR 71.01 Xetra close of October 20, 2026.

RBC target leaves 2.01 percent upside

Markets Insider reported on October 20, 2026 that RBC Capital maintained a Hold rating and a EUR 75.00 price target for Sanofi. The target was 2.01 percent above the EUR 73.52 market price at Lang & Schwarz.

EUR 73.52 versus the yearly range

Sanofi's 52-week range was EUR 69.77 to EUR 90.75 as of October 20, 2026. The current euro price was 5.38 percent above the low and 18.99 percent below the high, placing the stock nearer the lower end of its yearly band than its upper boundary.

What does the EUR 75.00 target imply?

The near-term analyst target leaves only 2.01 percent between the current euro price and RBC Capital's level. That narrow gap contrasts with the 18.99 percent distance to the 52-week high and gives the scheduled results a clear valuation reference.

October 30 results set the next date

Sanofi's investor calendar lists third-quarter 2026 results for October 30, 2026, including a management presentation and question-and-answer session, according to Sanofi. The same calendar lists the Jefferies Global Healthcare Conference in London for November 17, 2026, with Thomas Triomphe scheduled to speak about vaccines.

Sanofi price and investor perspective

The stock's immediate market position is defined by the 3.54 percent move above the prior Xetra close, the EUR 75.00 RBC target and the upcoming October 30 reporting date. Sanofi is listed on Euronext Paris and belongs to the CAC 40.

Sanofi was trading at EUR 73.52 at Lang & Schwarz on October 21, 2026 at 3:02 p.m. CEST, 3.54 percent above the Xetra close of October 20, 2026 at EUR 71.01. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.